SCHEMBL17640593

SCHEMBL17640593

COc1ccc(CNc2cc(C(=O)N(C)OC)c(Cl)nn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
VNN1 O95497 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ASPH Q12797 2/20 0.42
KDM8 Q8N371 2/20 0.42
RIOX2 Q8IUF8 1/20 0.42
PDE5A O76074 1/20 0.41
CASP1 P29466 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
HPGD P15428 1/20 0.40
POLB P06746 1/20 0.40
HSP90AA1 P07900 1/20 0.40
CLK4 Q9HAZ1 1/20 0.39
FFAR1 O14842 1/20 0.39
ALDH1A1 P00352 1/20 0.39
THRB P10828 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17640655 0.83 HIF1A (0.44) MAPTNPC1RAB9AVNN1KDM4E
SCHEMBL17640730 0.80 PIK3CD (0.50) MAPTCASP1KMT2AMEN1HSP90AA1
SCHEMBL6086559 0.77 MEN1 (0.46) MAPTNPC1RAB9AVNN1KDM4E
SCHEMBL25371238 0.76 TUBB4A (0.47) MAPTVNN1KDM4EASPHKDM8
SCHEMBL30590399 0.76 TUBB4A (0.47) MAPTVNN1KDM4EASPHKDM8
SCHEMBL17640756 0.74 NPC1 (0.50) MAPTNPC1RAB9AVNN1PDE5A
SCHEMBL17640648 0.71 ALDH1A1 (0.46) RAB9AKDM4ECASP1KMT2AMEN1
SCHEMBL370679 0.70 L3MBTL1 (0.44) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL15130283 0.70 NPBWR1 (0.44) MAPTNPC1RAB9AVNN1KDM4E
SCHEMBL370570 0.70 CACNA1G (0.45) MAPTNPC1RAB9AVNN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10611777-B2 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2020-04-07 US disclosed
US-10611777-B2 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2020-04-07 US disclosed
US-20190127391-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LTD (CN) 2019-05-02 US disclosed
US-20190127391-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LTD (CN) 2019-05-02 US disclosed
US-10208066-B2 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2019-02-19 US disclosed
US-10208066-B2 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2019-02-19 US disclosed
US-20170253618-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2017-09-07 US disclosed
US-20170253618-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2017-09-07 US disclosed
WO-2016045591-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253618-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE PIK3R5, PIK3CD, PIK3CB MAPT 4544/4885NPC1 2690/4885RAB9A 531/4885
US-10208066-B2 Imidazopyridazine compounds and their use PIK3R5, PIK3CD, INPP5D MAPT 4517/4885NPC1 2771/4885RAB9A 634/4885
US-20190127391-A1 NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE PIK3R5, PIK3CD, PIK3CB MAPT 4544/4885NPC1 2690/4885RAB9A 531/4885
US-10611777-B2 Imidazopyridazine compounds and their use PIK3R5, PIK3CD, INPP5D MAPT 4517/4885NPC1 2771/4885RAB9A 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.